# Unjha Formula (NSE: UNJHAFOR) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/UNJHAFOR · Pivot · prices to 22 Oct 2026

With a market capitalisation of ₹8 Cr, it ranks 3984th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 13.0% in FY25. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹3 Cr (−8.3% year on year) and net profit ₹0 Cr (−59.0%), on a standalone basis. Promoters held 36.92% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹8 Cr |
| ROE | 13.0% (FY25) |
| ROCE | 16.9% (FY25) |
| Debt to equity | 0 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹3 Cr | −8.3% | ₹0 Cr | −59.0% | ₹0.35 |
| Q4 FY26 | ₹3 Cr | +38.4% | −₹1 Cr | — | −₹1.66 |
| Q3 FY26 | ₹4 Cr | +17.3% | ₹0 Cr | +9.1% | ₹0.53 |
| Q2 FY26 | ₹4 Cr | +13.5% | ₹1 Cr | — | ₹1.83 |
| Q1 FY26 | ₹4 Cr | −8.6% | ₹0 Cr | −44.3% | ₹0.90 |
| Q4 FY25 | ₹2 Cr | −46.5% | −₹0 Cr | — | −₹0.91 |
| Q3 FY25 | ₹4 Cr | −32.3% | ₹0 Cr | −43.6% | ₹0.50 |
| Q2 FY25 | ₹4 Cr | −20.6% | −₹0 Cr | — | −₹0.25 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹14 Cr | ₹0 Cr |
| FY24 | ₹19 Cr | ₹0 Cr |
| FY23 | ₹13 Cr | ₹0 Cr |
| FY22 | ₹14 Cr | ₹0 Cr |
| FY21 | ₹10 Cr | ₹0 Cr |
| FY20 | ₹11 Cr | ₹0 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 36.92%
- Non-institutions: 63.08%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Clinitech Labor](https://app.pivotnow.in/stock/CTLLAB) | — | ₹9 Cr | — | — |
| [Genomic Valley](https://app.pivotnow.in/stock/GVBL) | — | ₹9 Cr | — | — |
| [Trinity League](https://app.pivotnow.in/stock/TRINITYLEA) | — | ₹8 Cr | — | — |
| [Adline Chem Lab](https://app.pivotnow.in/stock/ADLINE) | — | ₹8 Cr | — | — |
| [Dr Lalchandani](https://app.pivotnow.in/stock/DLCL) | — | ₹7 Cr | — | — |
| [Vivanza Bio](https://app.pivotnow.in/stock/VIVANZA) | — | ₹7 Cr | — | — |

## Questions and answers

### What is the market cap of Unjha Formula?

Unjha Formula's market capitalisation is ₹8 Cr (₹8 Cr) at the 22 Oct 2026 close, ranking 3984th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Unjha Formula?

Return on equity was 13.0% in FY25 and return on capital employed was 16.9% in FY25 (standalone figures).

### Is Unjha Formula a debt-free company?

Unjha Formula is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Unjha Formula's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Unjha Formula reported revenue of ₹3 Cr, −8.3% year on year, and net profit of ₹0 Cr, −59.0% year on year.

### What is the shareholding pattern of Unjha Formula?

As of 30 Jun 2026: promoters 36.92%, non-institutions 63.08%.

### Who are Unjha Formula's competitors?

The listed Pharma & Healthcare companies closest to Unjha Formula by market cap are Clinitech Labor, Genomic Valley, Trinity League, Adline Chem Lab, Dr Lalchandani and Vivanza Bio.

### Is Unjha Formula a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Unjha Formula's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on UNJHAFOR against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.